Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia

Neuropharmacology
Vanessa C AbílioRoberto Frussa-Filho

Abstract

Tardive dyskinesia, the most serious iatrogenic movement disorder, has been tentatively associated with nigrostriatal dopaminergic supersensitivity and with oxidative stress. It is also suggested that long-term neuroleptic treatment does not cause oral dyskinesia (OD), but interacts with some substrate of brain aging, resulting in the premature emergence of OD, that can occur spontaneously with aging. In order to investigate a possible role of nigrostriatal dopaminergic supersensitivity and of oxidative stress in aging- and reserpine-induced OD, the stereotyped behavior induced by dopaminergic agonists, a functional index of dopaminergic striatal activity, as well as the striatal antioxidant enzymes glutathione peroxidase and catalase were assessed. We demonstrate that, opposite to normotensive Wistar rats (NWR), spontaneously hypertensive rats (SHR) do not develop aging- or reserpine-OD. There were no differences between NWR and SHR in stereotyped behavior or in striatal glutathione peroxidase activity. Adult and old SHR presented higher striatal catalase activity relative to NWR, and aging increased it only in SHR. The catalase inhibitor aminotriazole reverted the absence of aging- and reserpine-induced OD in SHR. Our results...Continue Reading

References

Sep 1, 1976·European Journal of Pharmacology·P SetlerG McKenzie
Jun 1, 1992·The American Journal of Psychiatry·M F EganR J Wyatt
Dec 1, 1991·Archives of General Psychiatry·J B Lohr
Apr 1, 1990·The American Journal of Psychiatry·A M ElkashefD Barrett
Feb 15, 1989·Biochemical Pharmacology·M Strolin Benedetti, P Dostert
Oct 1, 1989·The Biochemical Journal·A M AdamoA Boveris
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Wolfarth, K Ossowska
May 31, 1994·Annals of the New York Academy of Sciences·G S Roth, J A Joseph
Jun 3, 1996·European Journal of Pharmacology·J L NeisewanderA N Sussman
Feb 14, 1998·Neurobiology of Aging·M BergamoR Frussa-Filho
Mar 26, 1998·Experimental Neurology·D L MarcusM L Freedman
Aug 29, 1998·Journal of Neurochemistry·Y Sagara
Oct 14, 1998·Progress in Neurobiology·R J Reiter
Oct 17, 1998·European Journal of Pharmacology·C M QueirozR Frussa-Filho
Oct 18, 2000·Free Radical Biology & Medicine·E Cadenas, K J Davies
Feb 24, 2001·Journal of Neural Transmission·R GaliliD Offen
Feb 2, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Patricia R V CalventeFilho Roberto Frussa
Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Bernardo Dubrovsky
May 16, 2002·British Journal of Pharmacology·Pattipati S NaiduShrinivas K Kulkarni
Jun 8, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·Pierre-Michel LlorcaChristophe Lancon
Jun 20, 2002·Psychopharmacology·V C AbílioR Frussa-Filho
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vanessa C AbílioRoberto Frussa-Filho

❮ Previous
Next ❯

Citations

Jun 7, 2005·Pharmacology, Biochemistry, and Behavior·Roselei FachinettoJoão B T Rocha
Jun 15, 2005·Pharmacology, Biochemistry, and Behavior·Marilise E BurgerJoão B T Rocha
Dec 14, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Mahmoud M El-Mas, Abdel A Abdel-Rahman
Apr 9, 2011·Journal of Neural Transmission·Romaiana Picada PereiraJoão Batista Teixeira Rocha
Oct 31, 2015·Psychopharmacology·Catiuscia Molz de FreitasRoselei Fachinetto
Mar 27, 2012·Behavioural Brain Research·Valéria S FernandesRegina H Silva
Dec 27, 2008·Pharmacology, Biochemistry, and Behavior·Angélica M TeixeiraMarilise E Bürger
Aug 3, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Roselei FachinettoJuliano Ferreira
Apr 20, 2005·Behavioural Brain Research·Marcello F PeixotoVanessa C Abílio
Nov 25, 2004·Brain Research Bulletin·Nilza P AraujoRoberto Frussa-Filho
Aug 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Regina H SilvaRoberto Frussa-Filho
Jun 20, 2006·Brain Research Bulletin·Marilise E BurgerJoão B T Rocha
Feb 7, 2006·Brain Research Bulletin·Juliana P M V CastroVanessa C Abílio
Sep 16, 2005·Epilepsy Research·Marinei Cristina Pereira RibeiroCarlos Fernando Mello
Aug 13, 2005·Physiology & Behavior·V P RicardoV C Abílio
Jan 24, 2012·Pharmacology, Biochemistry, and Behavior·Alcindo BusanelloNilda B V Barbosa
Feb 16, 2010·Biochimica Et Biophysica Acta·Pedro A JoseRobin A Felder
Feb 11, 2015·Pharmacology, Biochemistry, and Behavior·Mao-Hsien WangCheng-Chia Tsai
Jun 23, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Raquel LevinVanessa Costhek Abílio
Jan 15, 2013·Pharmacology, Biochemistry, and Behavior·Patrícia ReckziegelRoselei Fachinetto
Jul 2, 2008·European Journal of Pharmacology·Mahendra BishnoiShrinivas K Kulkarni
Oct 14, 2016·Frontiers in Pharmacology·Fernanda F PeresVanessa C Abílio
Jun 17, 2006·International Review of Psychiatry·Krishna VaddadiJohn Waddington
Apr 10, 2018·Neurotoxicity Research·Hung-Sheng SoungHsiang-Chien Tseng
Nov 28, 2018·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Jose I A Beserra-FilhoAlessandra M Ribeiro
Aug 6, 2021·Clinical and Experimental Pharmacology & Physiology·Suellen Silva-MartinsAlessandra Mussi Ribeiro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here